CD274 and neoplasm: Our major finding using IHC was the discovery of a significant difference between responders and nonresponders to anti-PD-(L)1 immunotherapy treatment, based upon neutrophil defensin expression on both tumor cells (p = 0.027) as immune cells (p = 0.043).